Online inquiry

IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11443MR)

This product GTTS-WQ11443MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets NT5E gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001204813.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4907
UniProt ID P21589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ11443MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5364MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ10577MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ8604MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuM195
GTTS-WQ9888MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ10477MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY-2951742
GTTS-WQ15431MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TSR-033
GTTS-WQ13238MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-05335810
GTTS-WQ12295MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MSB-0010718C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW